A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

Autor:	D. L. Klein, Pietro Panei, A. Anemona, William C. Blackwelder, Anna Giammanco, Alberto Eugenio Tozzi, Donato Greco, S. G. F. Wassilak, Stefania Salmaso, M L Ciofi Degli Atti, Paola Mastrantonio, Marina Giuliano
Rok vydání:	1996
Předmět:	business.industry Diphtheria Filamentous haemagglutinin adhesin General Medicine medicine.disease Pertussis toxin complex mixtures Virology Vaccination Immunology medicine Diphtheria-Tetanus Vaccine Pertactin business Diphtheria-Tetanus-acellular Pertussis Vaccines Whooping cough
Zdroj:	New England Journal of Medicine. 334:341-349
ISSN:	1533-4406 0028-4793
DOI:	10.1056/nejm199602083340601
Popis:	Background Concern about both safety and efficacy has made the use of whole-cell pertussis vaccines controversial. In some European countries, including Italy, the rate of vaccination against pertussis is low. Methods We conducted a double-blind trial in Italy in which infants were randomly assigned to vaccination at two, four, and six months of age with an acellular pertussis vaccine together with diphtheria and tetanus toxoids (DTP); a DTP vaccine containing whole-cell pertussis (manufactured by Connaught Laboratories); or diphtheria and tetanus toxoids without pertussis (DT). The acellular DTP vaccine was either one containing filamentous hemagglutinin, pertactin, and pertussis toxin inactivated with formalin and glutaraldehyde (SmithKline Beecham) or one with filamentous hemagglutinin, pertactin, and genetically detoxified pertussis toxin (Chiron Biocine). Pertussis was defined as 21 days or more of paroxysmal cough, with infection confirmed by culture or serologic testing. Results The efficacy of eac...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::031d8587fa7e8bd33e2bf1efd77f842a https://doi.org/10.1056/nejm199602083340601 Zobrazit plný text záznamu